SCHEMBL2963385

SCHEMBL2963385

CCOC(=O)COCCOC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.46
MGAM O43451 1/20 0.46
SI P14410 1/20 0.46
MGAM2 Q2M2H8 1/20 0.46
ALDH1A1 P00352 7/20 0.43
TRPA1 O75762 1/20 0.43
TSHR P16473 3/20 0.40
ALOX15 P16050 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP1A2 P05177 1/20 0.38
HSD17B10 Q99714 2/20 0.37
LMNA P02545 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
SOAT1 P35610 1/20 0.36
THRB P10828 1/20 0.35
ELANE P08246 1/20 0.35
NLRP3 Q96P20 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5359530 0.98 GAA (0.44) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL2965176 0.98 GAA (0.44) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL12967099 0.98 GAA (0.44) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL4849311 0.98 GAA (0.44) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL11163358 0.91 GAA (0.55) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL28174051 0.91 ALDH1A1 (0.40) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL28137354 0.91 ALDH1A1 (0.40) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL6665142 0.89 GAA (0.52) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL28316299 0.86 GAA (0.50) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL9275566 0.86 TSHR (0.41) ALDH1A1TSHRTDP1CYP3A4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110893236-A Lysosome-targeted antibody drug conjugate and application thereof 中山大学 2020-03-20 CN claimed
CN-109759047-A Preparation method of barium strontium titanate aerogel photocatalyst 南京工业大学 2019-05-17 CN claimed
CN-109731606-A Preparation method of N-doped barium strontium titanate aerogel photocatalyst 南京工业大学 2019-05-10 CN claimed
CN-109160533-A Blocky SrTiO3Method for producing aerogels 南京工业大学 2019-01-08 CN claimed
CN-102317391-B Silane coating compositions containing silicon-based polyether copolymers, methods for coating metal surfaces and articles made therefrom MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2014-10-15 CN claimed
EP-1651698-B1 ISOCYANATE-FREE PRIMER COMPOSITION FOR GLASS AND GLASS CERAMICS SIKA TECHNOLOGY AG (CH) 2012-09-12 EP claimed
CN-102317391-A Contain the method for silane coating compositions based on the copolyether of silicon, coating metal surfaces and by the goods of its preparation MOMENTIVE PERFORMANCE MAT INC 2012-01-11 CN claimed
CN-101090883-A Substituted hydroxyethylamines ELAN PHARM INC (US) 2007-12-19 CN claimed
US-20070043196-A1 Isocyanate-free primer composition for glass and glass ceramics SIKA TECHNOLOGY AG (CH) 2007-02-22 US claimed
US-7041721-B2 Highly neutralized polymer golf ball compositions including oxa acids and methods of making same ACUSHNET COMPANY (US) 2006-05-09 US claimed
EP-0910362-B1 OXA ACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS AVON PROD INC (US) 2004-10-27 EP claimed
US-20030225197-A1 Highly neutralized polymer golf ball compositions including oxa acids and methods of making same JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2003-12-04 US claimed
US-6534543-B2 Topical compositions with carboxy acid/ester, amide, or thioester/thioacid groups, with one or more of ether, amine, or sulfide groups; for example 3,6-dioxaheptanioic acid; peeling skin, softening hair AVON PRODUCTS, INC. 2003-03-18 US claimed
US-20020040056-A1 Oxa acids and related compounds for treating skin conditions AVON PRODUCTS, INC. 2002-04-04 US claimed
JP-2000511900-A 2000-09-12 JP claimed
EP-0910362-A4 OXA ACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS AVON PROD INC (US) 1999-12-22 EP claimed
EP-0910362-A1 OXA ACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS AVON PRODUCTS, INC. (US) 1999-04-28 EP claimed
US-5847003-A Oxa acids and related compounds for treating skin conditions AVON PRODUCTS, INC. (US) 1998-12-08 US claimed
US-5700316-A COMPRISED OF COLORANT AND VEHICLE OF POLY(ALKYLENE OXIDE) ALKYLATE OR DIALKYLATE OR POLYOXA-ALKANOIC ESTER OR DIESTER XEROX CORPORATION (US) 1997-12-23 US claimed
WO-1997046231-A1 OXA ACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS AVON PRODUCTS, INC. (US) 1997-12-11 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040056-A1 Oxa acids and related compounds for treating skin conditions OXGR1, OXA1L, CXCR1 GAA 1367/4885MGAM 1639/4885SI 1410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.